Johnson & Johnson’s New Application and 2 Drug Stocks with Regulatory News Now

Johnson & Johnson (NYSE:JNJ):  Johnson & Johnson applied for United States and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of  their Doxil cancer drug. Under JNJ’s plan, existing contract manufacturer Ben Venue Labs would produce Doxil, while a second supplier would handle other tasks such as ensuring the drug is sterile.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Eli Lilly (NYSE:LLY):  Shares of Eli Lilly popped after a new study showed that the experimental Alzheimer’s treatment, Solanezumab, slowed memory loss and cognitive decline by 30%, in early-stage patients. This offered the first evidence that a medication may hamper the course of the ailment.

Seattle Genetics (NASDAQ:SGEN):  After the Roche unit advanced two antibody-drug conjugates that use SGEN’s technology into Phase II trials, Seattle Genetics will receive undisclosed milestone payments from Genentech. The studies will evaluate the performance of the ADCs with Rituxan, which Genentech markets, in treating Non-Hodgkins Lymphoma and B-cell Lymphoma.

Don’t Miss: Is Pfizer’s Stock a Buy Now?